Last Price
65.98
Today's Change
+1.30 (2.00%)
Day's Change
64.50 - 70.94
Trading Volume
9,115,922
Market Cap
7 Billion
Shares Outstanding
110 Million
Avg Volume
3,781,562
Avg Price (50 Days)
56.86
Avg Price (200 Days)
42.93
PE Ratio
-71.72
EPS
-0.92
Earnings Announcement
23-Oct-2024
Previous Close
64.68
Open
65.62
Day's Range
64.5001 - 70.94
Year Range
8.28 - 99.41
Trading Volume
9,115,922
1 Day Change
2.01%
5 Day Change
32.12%
1 Month Change
39.23%
3 Month Change
-11.21%
6 Month Change
208.75%
Ytd Change
260.94%
1 Year Change
362.04%
3 Year Change
1071.94%
5 Year Change
744.81%
10 Year Change
724.75%
Max Change
724.75%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.